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Abstract 
There are several classifications of Pulmonary Hypertension, one of them being Pulmonary 
Arterial Hypertension (PAH). In cases in which the cause of PAH is unknown, the disease is 
referred to as Idiopathic Pulmonary Arterial Hypertension (IPAH). IPAH is an extremely rare 
disease, making it difficult to treat. However, over the past few decades, treatments have 
expanded and improved.  Treatments commonly used in clinical practice include one or more of 
the following: calcium channel blockers, prostacyclin derivatives, endothelin receptor 
antagonists, phosphodiesterase 5 inhibitors, guanylate cyclase stimulators, and in extreme cases 
lung transplants (single or double) or heart and lung transplants. The aim of this paper is to 
review the treatments and therapies available for IPAH because new information has been added 
after FDA approval of new medications. This article also raises ideas of possible future clinical 
trials to look at how these medications would work in a combination therapy. 
Keywords 
Idiopathic Pulmonary Arterial Hypertension, IPAH, primary pulmonary hypertension, PPH 
Introduction 
Blood is carried from the heart to the lungs via the pulmonary arteries.  Pulmonary hypertension 
(PH) occurs when the blood pressure in these arteries increases. PH can be classified into five 
groups, according to the World Health Organization Table 1.1 One of the groups is pulmonary 
arterial hypertension. PAH is divided into subgroups based on etiology and associated treatment 
options. The one of interest in this paper is idiopathic pulmonary arterial hypertension (IPAH), 
which is the diagnosis when the cause cannot be determined.2 Accompanying the increased 
blood pressure in the arteries, PAH is also classified by the vascular remodeling of the small 
pulmonary arteries.3 Because this remodeling causes damage, gradual resistance in the 
vasculature occurs often leads to right heart failure. This condition is often fatal because of its 
rapid progression.   
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Table 1: Pulmonary Hypertension Classifications.  [Based off Baliga R.S. et al. 2011, Figure 1.] 
1. Pulmonary Arterial 
Hypertension (PAH) 
2. Pulmonary 
Hypertension 
with Left Heart 
Disease 
3. Pulmonary 
Hypertension Due to 
Lung Diseases and/or 
Hypoxia 
4. Chronic 
Thromboembolic 
Pulmonary 
Hypertension 
5. Pulmonary 
Hypertension 
with Indistinct, 
Multi Factorial 
Mechanisms 
1.1 Idiopathic (IPAH) 
 
1.2 Heritable/Familial (FPAH) 
1.2.1 BMPR2 
1.2.2  ALK1, Endoglin 
1.2.3 Unknown 
1.3 Drug and Toxin-Induced 
 
1.4 Associated with (APAH) 
1.4.1. Connective Tissue 
Disorders 
1.4.2. HIV infection 
1.4.3. Portal Hypertension 
1.4.4. Congenital Heart 
disease 
1.4.5 Schistasamiasis 
1.4.6 Chronic Hemolytic 
Anemia 
 
1.5 Persistent Pulmonary 
Hypertension of the 
Newborn {PPHN} 
 
1’ Pulmonary Vena-occlusive 
Disease {PVOD} and Pulmonary 
Capillary Hemangiomatous {PCH} 
2.1  Systolic 
Dysfunction 
2.2 Diastolic 
Dysfunction 
2.3 Valvular 
Disease 
3.1 Chronic Obstructive 
Pulmonary Disease 
(COPD) 
3.2 Interstitial Lung 
Disease 
3.3 Other Pulmonary 
Diseases with Mixed 
Restrictive and 
Obstructive Patten 
3.4 Sleep Disordered 
Breathing 
3.5 Alveolar 
Hyperventilation 
Disorders 
3.6 Chronic Exposure of 
High Altitude 
3.7 Developmental 
Abnormalities 
 5.1 Hematological 
Disorders 
5.2 Systemic 
Disorders 
5.3 Metabolic 
Disorders 
5.4 Others   
 
IPAH is uncommon with an incidence of occurrence in one in every one million patients. 
Clinical research opportunities are limited due to the rarity of this disease.2 This review article is 
aimed to describe the available treatment options of IPAH. Current medications prescribed to 
these patients include calcium channel blockers, endothelin receptor antagonists, vasodilators, 
etc. The fatal outcome of IPAH can be slowed but not stopped.  
Background 
Diagnostic Process 
The first indications of PH include fatigue, dizziness, lethargy, and dyspnea. If a patient presents 
with these symptoms along with a chest pressure, chronic cough, shortness of breath, swollen 
legs, the process to confirm the diagnosis and causation begins.4 The diagnostic approach is 
similar within the five groups of PH. As with most diagnoses, the approach starts with a physical 
exam and patient history. Further screening is performed by use of an echocardiogram, which 
permits a noninvasive diagnostic method. To confirm the diagnosis the gold standard is 
performance of a right heart catheterization. Both the echocardiogram and right heart 
catheterization are used to measure pulmonary artery systolic pressure, but often agreement 
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between the two is limited. If mean right heart catheterization pressure exceeds 25 mmHg, a 
diagnosis of PAH is suspected.4 Even if the pressure is determined to be low, it is not sufficient 
to exclude PAH as a possible diagnosis. Other indications to consider are right arterial or 
ventricular enlargement, systolic dysfunction, hypertrophy, etc.5   
Other tests to confirm the diagnosis, potential causes, and determination of medication for PAH 
include blood tests, blood vessel test, chest x-ray, CT scan, MRI, pulmonary function tests, and 
ventilation/perfusion scan. The most common test used to evaluate the prognosis of a patient is 
the 6-minute walk test, which is also often the test used in determining the efficacy, during 
clinical trials, of treatments for diseases such as PAH. IPAH is a diagnosis of exclusion; 
therefore if the cause cannot be determined using a variety of tests, a diagnosis of IPAH is 
made.6 A simplified version of the diagnostic process, created using information from the 
Cleveland Clinic, can be seen in Figure 1.7  
Figure 1. Outlines stages of the diagnostic process recommended by the Cleveland clinic.7 CT,    
computed tomography; ECG, electrocardiogram; HIV, human immunodeficiency 
virus; PH, PAH, pulmonary arterial hypertension; TT, transthoracic; VO2, oxygen 
consumption. 
 
 
Molecular Pathways Involved 
Currently, three pathways are implicated (Figure 2); these pathways include the endothelin (ET), 
prostacyclin, and NO pathways and are targets for the current drug therapies. Figure 2 was 
created using information from several others.8-11 Approved PAH therapies include ET receptor 
antagonists (ERAs), prostacyclin derivatives, phosphodiesterase-5 (PDE5) inhibitors, and a 
soluble guanylate cyclase (sGC) stimulator. 
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Figure 2: The known pathways in PAH Targeted pathways and the therapies that affect them. 
Green arrows denote an increase in the intracellular concentration, red arrows indicate 
blockage of a receptor, inhibition of an enzyme or a decrease in the intracellular 
concentration. ET= endothelin; PDE-5 = phosphodiesterase type 5; sGC= soluble 
guanylate cyclase. [Figure created using combined information from Burger, C.D et al. 
2016, Zhang, Y. et al. 2012 and Humber, M. 2004] 
 
Methods 
The articles were obtained using PubMed, Medline, google, and google scholar.  Clinical trials 
were only included in this review article if the medication of interest was approved by the FDA 
for the use of IPAH.  Within the previously mentioned databases multiple phrases were searched 
including: “idiopathic pulmonary arterial hypertension”, “pulmonary arterial hypertension”, 
“clinical trial AND IPAH”, “treatments for idiopathic pulmonary arterial hypertension”, etc. 
After finding treatment options for IPAH a google search was conducted to find FDA approved 
medications; once found, PubMed, Medline, and google scholar were used to find the clinical 
trials involved in these FDA approvals. Because IPAH is a rare disease, there was no restriction 
applied to the date of publication.  
Treatments and Therapies 
Up until 1996 the gold standard of treatment for IPAH, then called primary pulmonary 
hypertension, included the use of anticoagulants, calcium channel blockers (CCB), and/or the use 
of oxygen therapy.12 As of 2013, all other FDA approved medications fell into three categories: 
prostacyclin derivatives, endothelin receptor antagonists (ERA), phosphodiesterase 5 inhibitors 
(PDE-5).3 More recently, a new drug class, guanylate cyclase stimulators, was added to 
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suggested treatments of IPAH. In severe cases in which medications are no longer efficacious, 
transplantations of lung(s) or heart and lungs are considered.  
Prostacyclin Derivatives 
Prostacyclins became of interest when the medical field discovered that levels were low in PAH 
patients. The discovery was made by Moncada, S. et. al. in 1976.13  Prostacyclins are 
vasodilators that inhibit platelet accumulation and have anti-proliferative properties. The three 
major prostacyclin derivatives used are epoprostenol, treprostinil, and iloprost. The recently 
approved medication Selexipag is included in this group as well. 
Epoprostenol was first approved by the FDA in 1995. It is continuously administered 
intravenously using an infusion pump, due to its short half-life of only six minutes. Because of 
this, infusion interruption is a concern.5 Reservoir cartridges must be changed every eight hours 
(without the use of ice packs) because of the instability of the medication at room temperature. 
Even with the use of ice packs it must be changed every twenty-four hours. With the short half 
life and needing to change the reservoir cartridge, patients are under time constraints to get the 
infusion pump up and running again. Another concern is that since a catheter is required for 
continuous infusion for an extended length of time, complications such as infection of the line 
and thrombosis arise. The major side effects of epoprostenol include but are not limited to: 
headache, hypotension, anxiety, chest pain, nausea, and vomiting.12 Overall, epoprostenol has 
been shown to have survival benefits, as well as to improve IPAH symptoms and exercise 
capacity.  
Almost a decade after the approval of epoprostenol, the FDA in 2002 approved treprostinil; it has 
side effects similar to that of epoprostenol with the addition of dizziness and jaw pain. 
Treprostinil has an extended half-life of about 4.5 hours, is chemically stable at room 
temperature, and has a pH that is neutral.12 It can be administered via infusion (intravenously or 
subcutaneously) or by inhaled formulations. Infusion site pain is a pragmatic association. Oral 
forms of treprostinil are currently under FDA review. But, missing oral doses could be 
potentially fatal and cause an abrupt return of symptoms.5,14  
Three years after the approval of treprostinil, iloprost was approved by the FDA. Iloprost is an 
inhaled prostacyclin derivative, but inconveniently requires 6-9 times of dosing per day.  
Because of the side effects that occur with infusion therapies, inhaled versions were developed to 
help alleviate those side effects. Although inhaled versions are a safer alternative, the number of 
doses per day required is a challenge for patient compliance. In addition to the side effects 
experienced with epoprostenol and treprostinil, iloprost side effects include but are not limited to 
muscle cramps, back pain, insomnia, and some altered tastes.12  
Ten years after iloprost hit the market selexipag was given the stamp of approval by the FDA in 
2015.  Selexipag is an oral medication that works by relaxing the muscles found in the blood 
vessel walls, which causes the blood vessels to dilate, allowing for the pressure to decrease. 
During the clinical trial stage it was shown to reduce hospitalization and slow progression of the 
disease.15  Side effects of selexipag are similar to the above mentioned: headache, muscle pain, 
diarrhea, jaw pain, nausea, vomiting, pain in extremities, (anemia), decreased appetite, and/or 
rash.  
29
Marshall Journal of Medicine, Vol. 3 [2017], Iss. 2, Art. 6
https://mds.marshall.edu/mjm/vol3/iss2/6
DOI: http://dx.doi.org/10.18590/mjm.2017.vol3.iss2.6
These prostacyclin derivatives all have risks and benefits but the choice of mechanism of 
administration varies per case.  
Endothelin Receptor Antagonists (ERA) 
Endothelin receptor antagonists (ERA) inhibit endothelin-1. In all forms of PAH, endothein-1 is 
typically overexpressed. ET-1 is one of the most potent vasoconstrictors and induces smooth 
muscle cell proliferation. ET-1 acts through receptors ET-A and ET-B. In patients with PAH, 
elevated levels of ET-1 are commonly seen in the circulation and in the lungs.16  
Three of the approved ERAs are bosentan, ambrisentan, and macitentan, which are all oral 
therapies. They have been shown to increase exercise tolerance and avoid clinical worsening. 
Because they are highly teratogenic, all ERA medications require monthly pregnancy tests in 
women of child bearing potential. Potential side effects for ERAs, in addition to the side effects 
mentioned for the procyclin derivatives, include: cold and flu like symptoms, urinary tract 
infection, and bronchitis.5  
Liver functioning tests are mandatory monthly when taking bosentan due to the risk of 
hepatoxicity. Bosentan has binding affinities that are nonselective for both ET-A and ET-B. In 
2001, bosentan became the first oral treatment approved by the FDA for PAH and is prescribed 
to be taken twice daily.5 
The approval of ambrisentan did not come until 2007. Ambrisentan is taken once daily and has 
greater sensitivity for ET-A than it does for ET-B. Because of this, it is possible that it can 
modify the vasoconstriction of the smooth muscle in the vasculature without the inhibitor effects 
on the vasodilators.12  
In 2013, macitentan was approved by the FDA. Macitentan has a greater binding affinity for ET-
B but can also bind to ET-A and is taken once daily. It is a derivative of bosentan with a slightly 
modified structure. The reason for the modification was to improve the safety and efficacy. It 
may be prescribed to be taken alone or in addition to phosphodiesterase 5 inhibitors and 
prostacyclin derivatives.17,18  
Phosphodiesterase 5 Inhibitors (PDE-5) 
The nitric oxide (NO) pathway is down-regulated. The cyclic GMP-mediated vasodilatory 
function of NO is impaired by phosphodiesterase 5 (PDE-5). PDE-5 inhibitors hinder this 
impairment and allow for NO-mediated vasodilation. This mechanism is dependent on NO 
availability.3,5,19 There are currently two PDE-5 inhibitors approved for the treatment of IPAH: 
sildenafil and tadalafil.  
The first PDE-5 inhibitor was sildenafil, which was approved by the FDA in 2009. Sildenafil 
works as a vasodilator, allowing for better blood flow in the pulmonary arteries. It is also used to 
treat erectile dysfunction but has been shown to improve functional class, or the extent of heart 
failure, and improve exercise tolerance.5 Sildenafil is generally prescribed to be taken three times 
daily, unless dealing with a more severe case of PAH. Side effects of sildenafil include but are 
not limited to memory problems, back pain, loss of hearing, ringing in the ears, and/or dizziness. 
Physicians should be aware that when sildenafil is taken along with the ERA bosentan, the two 
drugs co-interact and sildenafil levels decrease while bosentan levels increase (putting patient at 
further risk for hepatoxicity).14  
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It wasn’t until eight years later that the second PDE-5 inhibitor, tadalafil, was approved by the 
FDA. Tadalafil also improves exercise tolerance and slows disease progression.5 Side effects for 
tadalafil include upper respiratory tract infection, back pain, myalgia, cough, and/or nasal 
congestion.  It was approved by the FDA for use starting at 40 mg.12,20 
Guanylate Cyclase Stimulators 
Extensive literature research demonstrated that the only reported FDA approved guanylate 
cyclase stimulator for IPAH is riociguat, approved in 2013. Riociguat side effects include 
gastroesophageal reflux disease, and the combination of side effects listed for the prostacyclin 
derivatives. The mechanisms of riociguat work by relaxing the arteries, causing the blood 
pressure to decrease and blood flow to increase. Riociguat is taken three times daily and was 
shown to have a positive effect on improving exercise tolerance. Physicians must be aware that 
female patients must be enrolled in Adempas Risk Evaluation and Mitigation Strategy (REMS) 
program to be able to receive the drug. This program sets contraception guidelines as well as 
regular pregnancy testing for all women taking riociguat.  The reason for this is that riociguat can 
harm a developing fetus; therefore, women in child-bearing years must take certain precautions 
that are outlined in the program.21,22  
Table 2 summarizes the updated medications and the pathways that they are involved in; it was  
created based on information in Table 1 from Ruiz, G. et. al.23  
 
Table 2. Medication and the mechanism of action for PAH.  
 
Transplantations   
If medications do not work or lose efficacy, the remaining treatment option is to perform a lung 
or heart and lung transplant. The possible transplant types include: single lung transplant, double 
lung transplant, or heart and lung transplant. The median survival rate after lung transplant is 4.9 
years and the median survival rate after both heart and lung transplant is 5 years. Most deaths 
after transplantation occur within the first year.24 Consideration of transplant is recommended 
early in disease progression in order to be evaluated for the transplant list and allow adequate 
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survival time until a transplant becomes available.12  Limitations of transplantation include the 
possibility of rejection, limited number of organs that become available, and also finding the 
perfect match.  
Combination Treatments and Therapies 
Research considering the use of a combination of treatment and therapies has been limited and 
mostly observational. One clinical trial in 2008 showed promising results for IPAH using the 
combination treatment of prostacyclin derivatives and PDE inhibitors, specifically epoprostenol 
and sildenafil. This was a 2-arm treatment group; one arm was taking only the maximum amount 
of epoprostenol while the treatment group (combination group) was taking both epoprostenol and 
sildenafil. The results included a statistically significant 6-minute walk distance increase and a 
greater decrease in pulmonary arterial pressure in the combination group.25   
A more recent clinical trial conducted a 3-arm clinical trial comparing ambrisentant vs. tadalfil 
vs. the combination of ambrisentan and tadalfil. The results of this study were published in 2015 
and showed an improvement in 6-minute walk distance but there were higher numbers of adverse 
events. Some of the adverse events included anemia, nasal congestion, headache and peripheral 
edema.26 Although there are no clinical trials to highly support the use of combination medicines 
and therapies, physicians often prescribe blood thinners, diuretics, digoxin, and oxygen therapy 
in addition to the single agent treatments listed above.6 At the physician’s discretion, a 
combination of the single agents may be prescribed.  This may happen if a patient fails to 
respond to the first therapy and completely changing to a single agent could result in regression 
of current clinical status.12 
Discussion 
There are limitations in diagnosing and managing the disease. Because of the disease incidence 
being low and the signs and symptoms being nonspecific, diagnosis can be a challenge. When a 
patient who presents with symptoms that are nonspecific, such as dyspnea or dizziness, and other 
diseases have been ruled out, PAH should be considered as a diagnosis by the physician. 
Echocardiography, as mentioned before, is a tool used in the diagnosis process. Overreliance on 
this test sometimes results in misclassification and management measures of the disease.  To 
help in selecting the right therapy and treatment of the disease, a patient should undergo right 
heart catheterization to get an accurate measure of the pressures and assess right ventricular 
function.  
Education of both public and healthcare providers could help increase awareness of the disease. 
This education could help result in consideration of this disease more often when 
cardiorespiratory disorders cannot be attributed to the patient symptoms.  With consideration of 
this disease more often, early referral is recommended of patients with suggestive symptoms or 
abnormal echocardiography, especially high risk population, to specialists in this field to confirm 
the diagnosis through right heart catheterization. Early referral could result in the patient getting 
the care they need quicker, leading to management of the disease which could result in better 
quality of life. The efficacy of these medications overall seem to improve quality of life, 
however, no cure has yet to be found.   
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Conclusion 
Over the past couple decades, the availability and quality of treatments and therapies have 
improved for IPAH. Although treatments and therapies have improved disease progression and 
survival rate, there is still no definite cure. Future research should target new classes of drugs in 
the effort to find a cure, as well as to explore the effectiveness of combination of treatments and 
therapies. Currently, there is no clear assertion as to which treatment is better; physicians should 
evaluate on a case-by- case basis. This review aimed to include all current FDA approved 
treatments and therapies for idiopathic pulmonary arterial hypertension, achieved through 
extensive literature research and confirmations from fda.gov. 
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